- Home
- STTK vs PESI Comparison
STTK vs PESI Comparison
Compare STTK & PESI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- PESI
- Stock Information
- Founded
- STTK 2016
- PESI 1990
- Country
- STTK United States
- PESI United States
- Employees
- STTK N/A
- PESI N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- PESI Environmental Services
- Sector
- STTK Health Care
- PESI Industrials
- Exchange
- STTK Nasdaq
- PESI Nasdaq
- Market Cap
- STTK 173.6M
- PESI 153.6M
- IPO Year
- STTK 2020
- PESI 1992
- Fundamental
- Price
- STTK $3.86
- PESI $10.53
- Analyst Decision
- STTK Strong Buy
- PESI Strong Buy
- Analyst Count
- STTK 3
- PESI 1
- Target Price
- STTK $10.67
- PESI $18.00
- AVG Volume (30 Days)
- STTK 150.7K
- PESI 86.1K
- Earning Date
- STTK 11-07-2024
- PESI 10-31-2024
- Dividend Yield
- STTK N/A
- PESI N/A
- EPS Growth
- STTK N/A
- PESI N/A
- EPS
- STTK N/A
- PESI N/A
- Revenue
- STTK $4,123,999.00
- PESI $72,199,000.00
- Revenue This Year
- STTK $164.45
- PESI N/A
- Revenue Next Year
- STTK N/A
- PESI $52.51
- P/E Ratio
- STTK N/A
- PESI N/A
- Revenue Growth
- STTK 380.09
- PESI N/A
- 52 Week Low
- STTK $1.33
- PESI $6.51
- 52 Week High
- STTK $11.76
- PESI $14.17
- Technical
- Relative Strength Index (RSI)
- STTK 57.18
- PESI 49.91
- Support Level
- STTK $3.37
- PESI $9.58
- Resistance Level
- STTK $3.75
- PESI $10.78
- Average True Range (ATR)
- STTK 0.24
- PESI 0.55
- MACD
- STTK 0.08
- PESI -0.04
- Stochastic Oscillator
- STTK 88.57
- PESI 50.26
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: Treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.